Recent advances in generative biology for biotherapeutic discovery
M Mock, CJ Langmead, P Grandsard… - Trends in …, 2024 - cell.com
Generative biology combines artificial intelligence (AI), advanced life sciences technologies,
and automation to revolutionize the process of designing novel biomolecules with …
and automation to revolutionize the process of designing novel biomolecules with …
Stability of Protein Pharmaceuticals: Recent Advances
MC Manning, RE Holcomb, RW Payne… - Pharmaceutical …, 2024 - Springer
There have been significant advances in the formulation and stabilization of proteins in the
liquid state over the past years since our previous review. Our mechanistic understanding of …
liquid state over the past years since our previous review. Our mechanistic understanding of …
Reduction of monoclonal antibody viscosity using interpretable machine learning
Early identification of antibody candidates with drug-like properties is essential for
simplifying the development of safe and effective antibody therapeutics. For subcutaneous …
simplifying the development of safe and effective antibody therapeutics. For subcutaneous …
Prediction of Antibody Viscosity from Dilute Solution Measurements
The high antibody doses required to achieve a therapeutic effect often necessitate high-
concentration products that can lead to challenging viscosity issues in production and …
concentration products that can lead to challenging viscosity issues in production and …
A comparative study of the developability of full-length antibodies, fragments, and bispecific formats reveals higher stability risks for engineered constructs
I Condado-Morales, F Dingfelder, I Waibel… - mAbs, 2024 - Taylor & Francis
Engineered antibody formats, such as antibody fragments and bispecifics, have the potential
to offer improved therapeutic efficacy compared to traditional full-length monoclonal …
to offer improved therapeutic efficacy compared to traditional full-length monoclonal …
Assessment and incorporation of in vitro correlates to pharmacokinetic outcomes in antibody developability workflows
T Jain, B Prinz, A Marker, A Michel, K Reichel… - Mabs, 2024 - Taylor & Francis
In vitro assessments for the prediction of pharmacokinetic (PK) behavior of biotherapeutics
can help identify corresponding liabilities significantly earlier in the discovery timeline. This …
can help identify corresponding liabilities significantly earlier in the discovery timeline. This …
Utility of physiologically based pharmacokinetic modeling to predict inter-antibody variability in monoclonal antibody pharmacokinetics in mice
S Liu, SC Humphreys, KD Cook, KP Conner… - Mabs, 2023 - Taylor & Francis
In this investigation, we tested the hypothesis that a physiologically based pharmacokinetic
(PBPK) model incorporating measured in vitro metrics of off-target binding can largely …
(PBPK) model incorporating measured in vitro metrics of off-target binding can largely …
Sequence-Based Viscosity Prediction for Rapid Antibody Engineering
Through machine learning, identifying correlations between amino acid sequences of
antibodies and their observed characteristics, we developed an internal viscosity prediction …
antibodies and their observed characteristics, we developed an internal viscosity prediction …
PROPERMAB: an integrative framework for in silico prediction of antibody developability using machine learning
B Li, S Luo, W Wang, J Xu, D Liu, M Shameem… - bioRxiv, 2024 - biorxiv.org
Selection of lead therapeutic molecules is often driven predominantly by pharmacological
efficacy and safety. Candidate developability, such as biophysical properties that affect the …
efficacy and safety. Candidate developability, such as biophysical properties that affect the …